Clinical Trials · NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 620
- Start date
- Dec 2022
- Locations
- 1 site, China
- Primary endpoint
- Overall response rate (ORR)